Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib

• Published in: Cardio-oncology (London, England) Vol. 7; no. 1; pp. 1 - 31
• Main Authors: Maruta, Shunsuke, Usami, Kyohei, Tajiri, Kazuko, Otani, Masafumi, Hiraya, Daigo, Watabe, Hiroaki, Hoshi, Tomoya, Sato, Akira, Ieda, Masaki
• Format: Journal Article
• Language: English
• Published: London BioMed Central 27.08.2021; BMC
• Subjects: Angina pectoris; Atherosclerosis; Cardiology; Cardiovascular disease; Case Report; Chronic illnesses; Chronic myeloid leukemia; Coronary angiography; Coronary circulation; Coronary spasm; Coronary vessels; Electrocardiography; Kinases; Leukemia; Medical imaging; Medical prognosis; Pain; Patients; Risk factors; Smooth muscle; Tyrosine kinase inhibitor; Vasospastic angina
• ISSN: 2057-3804; 2057-3804
• DOI: 10.1186/s40959-021-00119-6

Abstract Background Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), is highly effective in the treatment of patients with chronic myeloid leukemia (CML), despite being more vasculotoxic than older TKIs such as imatinib. Herein, we present a case of nilotinib-associated vasospastic angina confirmed by an acetylcholine spasm provocation test. Case presentation A 62-year-old CML patient treated with 300 mg nilotinib twice daily complained of several episodes of rest angina and was hospitalized at our institution. Coronary angiography revealed no severe organic stenosis, and the acetylcholine spasm provocation test confirmed the diagnosis of vasospastic angina. Although treatment with a calcium channel blocker and nicorandil reduced the frequency of chest pain, angina symptoms continued to occur. At 10 months post discharge, the patient complained of increased frequency of angina; therefore, the nilotinib dosage was reduced to 150 mg twice daily. Consequently, the patient reported a significant improvement in chest symptoms. Conclusions This case report highlights the potential vasculotoxic effects of nilotinib. Cardiologists and hematologists should be vigilant for coronary artery spasm as a possible vascular adverse event caused by nilotinib.